Aenova Group, a global CDMO headquartered in Starnberg, provides comprehensive services for the development, manufacturing, and packaging of drug products. With 4,000 employees across 14 sites, it has grown into one of the world’s top ten CDMOs under BC Partners’ ownership and CEO Jan Kengelbach’s leadership. In 2023, Aenova achieved record pro-forma revenue of € 832m, up 17% from the previous year.

Dominik de Daniel, CEO at Kühne Holding, commented, "With this investment, we are taking an important strategic step to enlarge our investment portfolio to include healthcare and pharmaceutical assets with a strong financial base and long-term growth prospects. Aenova Members of the Aenova Group C.P.M. - CPR - Dragenopharm - Haupt Pharma - Swiss Caps - SwissCo - Temmler is on a great performance track, and we are excited to accelerate it even further under our ownership."

BC Partners’ Chairman, Raymond Svider, added, “We’re pleased to see such an important German healthcare business continue its growth trajectory under the strategic ownership of Kühne Holding AG. As a firm, we have a long and successful history of partnering with families and founders across Europe, and we look forward to working closely with Kühne Holding and Aenova in this next chapter for the business.”

Jan Kengelbach, CEO at Aenova, said, "With the new ownership structure, we will continue to implement our strategy of making Aenova the go-to CDMO with market-leading capabilities and innovative specialty technologies in Europe. With its long-term investment horizon, Kühne Holding is a perfect fit for the business to support this strategy. It allows us to continue down the path of operational excellence in the conventional manufacturing business, while building highly sought-after technology platforms and development services to satisfy the customer demand of the future."